title: The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
abstract: BACKGROUND
  Hepatitis C virus (HCV) is the main agent of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma in the western world. It affects more than 170 million people worldwide. HCV treatment, based on the combination of Peg-interferon and ribavirin, is effective in about 50% of treated patients. Therefore, there is a need to develop new drugs active against HCV.
  
  
  METHODS
  Data were obtained by searching for all full articles on Medline and abstracts presented at major international congresses on viral hepatitis.
  
  
  RESULTS
  A review of clinical data about the efficacy and safety of telaprevir (VX-950), the HCV protease inhibitor that is in the most advanced phase of clinical development.
  
  
  CONCLUSIONS
  Telaprevir has an acceptable pharmacokinetic profile and seems to be a potent antiviral drug against HCV, although, owing to a low genetic barrier, resistant variants emerge within a few days when used in monotherapy, thereby decreasing its efficacy. Consequently, telaprevir has been combined with pegylated-interferon and ribavirin in clinical trials. This triple combination is more effective but has a higher rate of adverse events (notably rash) than the standard of care, despite the shorter duration of therapy.
authors.affiliation: Università di Napoli Federico II, Dipartimento di Medicina Pubblica e Sicurezza Sociale, Sezione di Malattie Infettive (Ed. 18), 80131 Naples, Italy.
authors.forename: Ivan
authors.initials: I
authors.lastname: Gentile
authors.forename: Maria Aurora
authors.initials: MA
authors.lastname: Carleo
authors.forename: Federico
authors.initials: F
authors.lastname: Borgia
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Castaldo
authors.forename: Guglielmo
authors.initials: G
authors.lastname: Borgia
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects* / Q000201:enzymology; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D015394:Molecular Structure; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors*; D014764:Viral Proteins / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
chemical_list: D000998:Antiviral Agents; D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D009842:Oligopeptides; D017361:Viral Nonstructural Proteins; D014764:Viral Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C455041:NS4A cofactor peptide, Hepatitis C virus; C486464:telaprevir